Summary

This article reviews data from the GO-AFTER Study [NCT00264550], the first prospective, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of a TNF inhibitor (golimumab) in patients with active rheumatoid arthritis who were previously exposed to another TNF inhibitor.